Journal of Medicinal Chemistry p. 405 - 409 (1987)
Update date:2022-08-04
Topics:
Haces, Alberto
Breitman, Theodore R.
Driscoll, John S.
Hexamethylenebis[acetamide] (HMBA) is an agent in clinical trial that induces differentiation of certain types of tumor cells to nonmalignant phenotypes. In an attempt to discover a more potent compound, a number of bis-functionalized amides, imides, and hydrazine derivatives of HMBA were prepared and evaluated in vitro with the HL-60 human promyelocytic leukemia cell line. Among the compounds evaluated, the 5,5-dimethylhydantoin derivative is almost 10 times more potent than HMBA in inducing differentiation. The bis-imide, diacetyl-HMBA is both more potent and effective than its parent compound. Six of the 16 compounds evaluated cause at least 20% differentiation. An inverse relationship between the degree of differentiation and the percentage of viable cells is described for HMBA and its analogues.
View MoreNanyang Tianhua pharmaceutical Co.,Ltd.
Contact:+8618639816203
Address:Longsheng Industrial Park
Beijing ZhongDaXinHe Chemical Product Co.,Ltd
Contact:010-52876516
Address:tongzhoubeiyuan
Zhejiang Sanmei Chemical Industry Co., Ltd
Contact:86-579-87633213
Address:Huchu Industrial Zone, Qingnian Rd., Wuyi County, Zhejiang Prov., China.
Beijing Mashi Fine Chemical Co.,Ltd.
Contact:+86-10-61271592
Address:Room 506, Section B, Kaichi Mansion, Industrial Development
Contact:86-25-58619180
Address:Nanjing High-Tech Zone 10 Xinghuo Road Pukou District Nanjing, Jiangsu 210061 The People's Republic of China
Doi:10.1021/ol8016929
(2008)Doi:10.1021/acs.orglett.7b02886
(2017)Doi:10.1016/S0040-4039(00)84013-7
(1986)Doi:10.1016/j.jorganchem.2008.06.013
(2008)Doi:10.1055/s-2008-1067145
(2008)Doi:10.1246/bcsj.81.796
(2008)